Skip to content
HomeLatest newsJanssen Pharmaceuticals releases a 2016 U.S. Transparency Report
A photo of a pharmacist holding a bottle of medicine

Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report

Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas, explains why Janssen is sharing information around its medication pricing and other business practices.

Share Article
share to

Johnson & Johnson has a legacy of leadership when it comes to transparency. And the Janssen Pharmaceutical Companies of Johnson & Johnson recognize that consumers in the U.S. are particularly concerned about the high cost of healthcare these days. That’s why the company just released a 2016 U.S. Transparency Report that includes information on pricing and other business practices, covering everything from discovery to the commercialization of pharmaceuticals.

“Our hope is that this report will address questions people may have, and that it will lead to more discussion about how we can work together to move toward a more value-based healthcare system—one that delivers what we all want: greater access to care at a more manageable cost, and, most importantly, better health for us all,” says Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas.

Watch this video of Taubert to learn more about the 2016 U.S. Transparency Report and how it can help better inform consumers.

hqdefault.jpg
2016 U.S. Transparency Report Jennifer Taubert

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.